{"id":28326,"date":"2016-10-11T18:36:57","date_gmt":"2016-10-11T16:36:57","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=28326"},"modified":"2016-10-11T19:03:03","modified_gmt":"2016-10-11T17:03:03","slug":"gilead-italia-lufficio-brevetti-europeo-conferma-il-brevetto-sul-sofosbuvir","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/gilead-italia-lufficio-brevetti-europeo-conferma-il-brevetto-sul-sofosbuvir\/","title":{"rendered":"Gilead Italy. The European Patent Office confirms the patent on sofosbuvir"},"content":{"rendered":"

Il brevetto che copre sofosbuvir rimane valido, in forma modificata su alcuni aspetti tecnici. Pertanto l\u2019azienda ritiene che la decisione dell\u2019Ufficio Brevetti Europeo rappresenti un\u2019ulteriore conferma della straordinaria innovazione che questo farmaco rappresenta per i pazienti. <\/em><\/p>\n

Nota stampa Gilead Italia<\/strong><\/p>\n

\"RisultatiL\u2019Ufficio Brevetti Europeo conferma il brevetto sul sofosbuvir<\/p>\n

Milano, 11 ottobre 2016 \u2013 Mercoled\u00ec scorso, 5 ottobre, l\u2019Ufficio Europeo dei Brevetti (European Patent Office, EPO) ha confermato il brevetto europeo sul sofosbuvir, farmaco di Gilead per il trattamento dell\u2019epatite C.<\/p>\n

La sezione dello European Patent Office dedicata ai ricorsi ha raggiunto questa decisione dopo due giorni di udienze, durante le quali i ricorrenti hanno avuto modo di presentare i propri argomenti per contestare la validit\u00e0 del brevetto.<\/p>\n

Il brevetto che copre sofosbuvir rimane valido, in forma modificata su alcuni aspetti tecnici. Pertanto l\u2019azienda ritiene che la decisione dell\u2019Ufficio Brevetti Europeo rappresenti un\u2019ulteriore conferma della straordinaria innovazione che questo farmaco rappresenta per i pazienti.<\/p>\n

__________________________________<\/p>\n

EPO maintains\u00a0<\/em>patent for hepatitis C drug in amended form<\/strong><\/p>\n

Munich, 5 October 2016 \u2013\u00a0<\/strong>The European Patent Office (EPO) has maintained\u00a0<\/strong>in an amended form\u00a0<\/em>European patent\u00a0EP 2203462<\/a>, granted to Gilead Pharmasset LLC in respect of a drug for the treatment of hepatitis C.\u00a0<\/strong>The decision was announced today at the end of public oral proceedings in the opposition procedure before the EPO. The patent had been contested by ten parties, including the NGO M\u00e9decins du Monde, pharmaceutical companies and IP law firms. It covers drug compounds and especially the active chemical agent Sofosbuvir marketed under various brand names.<\/p>\n

After hearing the parties\u00a0<\/em><\/strong>present, the EPO\u2019s Opposition Division (a body consisting of three experts in the relevant technical field and a patent law expert) came to the conclusion that after deletion of claims to single compounds, \u00a0European patent EP 2203462 \u00a0could be maintained\u200e in an amended form.<\/p>\n

The grounds for decision will be published on the\u00a0EPO website<\/a> in due course. The decision can be appealed by the parties before the EPO\u2019s second-instance judiciary, the Boards of Appeal.<\/p>\n

The patent application was filed at the EPO on 26 March 2008, and the European patent granted to Gilead on 21 May 2014. Oppositions were filed with the EPO in February 2015 by ten parties. The opponents had requested revocation of the patent in its entirety for reasons of non-compliance with legal provisions of European patent law including novelty of the invention and the inventive step applied. The patent owner had requested that the patent be maintained.<\/p>","protected":false},"excerpt":{"rendered":"

Il brevetto che copre sofosbuvir rimane valido, in forma modificata su alcuni aspetti tecnici. Pertanto l\u2019azienda ritiene che la decisione dell\u2019Ufficio Brevetti Europeo rappresenti un\u2019ulteriore conferma della straordinaria innovazione che questo farmaco rappresenta per i pazienti. Nota stampa Gilead Italia L\u2019Ufficio Brevetti Europeo conferma il brevetto sul sofosbuvir Milano, 11 ottobre 2016 \u2013 Mercoled\u00ec scorso, …<\/p>","protected":false},"author":4,"featured_media":28329,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[41,29],"class_list":["post-28326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-leggisentenze","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=28326"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/28326\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/28329"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=28326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=28326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=28326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}